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Renata C. Gallagher, Birgit Pils,* Mohammed Albalwi, and Uta Francke
Department of Genetics, Stanford University School of Medicine, Stanford, CA
Prior work has suggested that loss of expression of one or more of the many C/D box small nucleolar RNAs
(snoRNAs) encoded within the complex, paternally expressed SNRPN (small nuclear ribonuclear protein N) locus
may result in the phenotype of Prader-Willi syndrome (PWS). We suggest that the minimal critical region for PWS
is ∼121 kb within the 1460-kb SNRPN locus, bordered by a breakpoint cluster region identified in three individuals
with PWS who have balanced reciprocal translocations and by the proximal deletion breakpoint of a familial
deletion found in an unaffected mother, her three children with Angelman syndrome, and her father. The subset
of SNRPN-encoded snoRNAs within this region comprises the PWCR1/HBII-85 cluster of snoRNAs and the single
HBII-438A snoRNA. These are the only known genes within this region, which suggests that loss of their expression
may be responsible for much or all of the phenotype of PWS. This hypothesis is challenged by findings in two
individuals with PWS who have balanced translocations with breakpoints upstream of the proposed minimal critical
region but whose cells were reported to express transcripts within it, adjacent to these snoRNAs. By use of real-
time quantitative reverse-transcriptase polymerase chain reaction, we reassessed expression of these transcripts and
of the snoRNAs themselves in fibroblasts of one of these patients. We find that the transcripts reported to be
expressed in lymphoblast–somatic cell hybrids are not expressed in fibroblasts, and we suggest that the original
results were misinterpreted. Most important, we show that the PWCR1/HBII-85 snoRNAs are not expressed in
fibroblasts of this individual. These results are consistent with the hypothesis that loss of expression of the snoRNAs
in the proposed minimal critical region confers much or all of the phenotype of PWS.
Prader-Willi syndrome (PWS [MIM 176270]) is a neu-
rodevelopmental disorder characterized by neonatal
hypotonia and failure to thrive, hyperphagia leading
to obesity, mental retardation, hypogonadotropic hypo-
gonadism, characteristic facies, short stature, small hands
and feet, and behavioral abnormalities. Most individuals
with PWS have a 4–4.5-Mb deletion of their paternal
chromosome 15. PWS must derive from loss of function
of one or more paternally expressed genes within this
region. The same deletion confers Angelman syndrome
(AS [MIM 105830]) when inherited from the mother.
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Although a small number of patients with AS have mu-
tations in the preferentially maternally expressed gene
UBE3A, indicating that the gene is critical for the AS
phenotype, no analogous coding-region mutations have
been found in individuals with PWS. This has led to the
suggestion that PWS is due to loss of function of multiple
genes (Nicholls and Knepper 2001).
There are other causes of PWS that abrogate normal
paternal expression of genes in this region, such as ma-
ternal uniparental disomy (UPD) 15 and imprinting cen-
ter (IC) mutations (Nicholls and Knepper 2001). These
affect all paternally expressed genes in the region and
therefore are not helpful in determining the minimal crit-
ical region for PWS. Important clues to the subset of
genes responsible for PWS derive from patients with
chromosomal translocations that disrupt the region but
maintain its imprinted expression pattern. Balanced re-
ciprocal translocations with breakpoints distal to the IC
are rare causes of PWS (Nicholls and Knepper 2001).
In each of the five cases reported, the paternally derived
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Figure 1 The SNRPN locus, starting at the major promoter.A,
The large SNRPN transcript (black arrow). Several of the stable tran-
scripts are in blue: SNURF, exons 1–3; SNRPN, exons 4–10; PAR-5;
PWCR1; IPW and PAR-1. A subset of SNRPN exon sequences is
illustrated by thin black lines. SnoRNA sequences are indicated by red
lines and are identified by red text. The PWCR1/HBII-85 snoRNAs
are a cluster of 27 sequences, the HBII-52 snoRNAs are a cluster of
47 sequences. Most are located within SNRPN introns, and most
introns contain only one snoRNA. Not all are depicted, and the draw-
ing is not to scale. B, Derivation of the PWS minimal critical region
(box). Its borders are defined proximally by the wavy line that indicates
the distal breakpoint cluster region within the alternatively spliced
intron 20a/exon 21 (three individuals with PWS). The proximal break-
point cluster region is in intron 2, within the SNURF gene (two in-
dividuals with PWS, including the individual studied here). The distal
border of the minimal region is defined by the AS submicroscopic
deletion that did not confer PWS when paternally inherited (blackened
rectangle). The known genes and detected transcripts found within its
borders are depicted; these are the transcripts PWCR1, IPW, and PAR-
1 (blue) and the genes for snoRNAs HBII-438A and the PWCR1/
HBII-85 cluster (red).
chromosome 15 contains a translocation breakpoint
within the paternally expressed SNRPN (small nuclear
ribonuclear protein N) locus (Schulze et al. 1996; Sun
et al. 1996; Conroy et al. 1997; Kuslich et al. 1999;
Wirth et al. 2001).
Multiple alternatively spliced and alternatively poly-
adenylated transcripts originate at the SNRPN promoter
(Gray et al. 1999; Runte et al. 2001; Wirth et al. 2001).
Overlapping cDNA clones and exon connection RT-PCR
suggest that the largest transcripts are 1460 kb and con-
sist of at least 148 exons (Runte et al. 2001). Almost
all transcripts encode two mRNAs at the 5′ end (Gray
et al. 1999). Exons 1–3 encode a protein product of
unknown function termed “SNURF” (SNRPN upstream
reading frame) (Gray et al. 1999). Exons 4–10 encode
SNRPN (SmN), a homolog of the SmB/B′ protein that
binds small nuclear RNAs (snRNAs) involved in mRNA
splicing. SmN replaces SmB/B′ in the brain (reviewed in
Nicholls and Knepper 2001). An unusual feature of the
large SNRPN transcripts is that multiple introns down-
stream of the protein-coding regions contain C/D box
small nucleolar RNA (snoRNA) genes. There are two
large multi–snoRNA gene clusters, three single-copy
snoRNA genes, and one snoRNA gene present in two
copies separated by 240 kb (Runte et al. 2001). Most
introns contain only one snoRNA gene, and most
snoRNAs are within introns (Runte et al. 2001). A sim-
plified schematic of the SNRPN transcript, with ap-
proximate locations of snoRNA genes (Cavaille et al.
2000; de los Santos et al. 2000; Meguro et al. 2001;
Runte et al. 2001), is shown in figure 1A. A similar
organization has been reported for the maternally ex-
pressed Meg8 noncoding RNA gene at 14q32, which
also encodes multiple C/D box snoRNAs within its in-
trons; there are two snoRNA gene clusters, and there is
one individual snoRNA gene (Cavaille et al. 2002).
Among the five individuals who have features of PWS
together with translocations, the breakpoints cluster into
two regions: within SNRPN intron 2 (two individuals)
(Kuslich et al. 1999; Sun et al. 1996) and within the
untranslated, alternatively spliced, large (130-kb) exon
20/intron 20a (three individuals) (Schulze et al. 1996;
Conroy et al. 1997; Wirth et al. 2001). These define a
promoter-proximal and a promoter-distal breakpoint
cluster region within SNRPN (fig. 1B). We have chosen
the promoter-distal translocation breakpoint cluster re-
gion as the upstream border of a proposed minimal crit-
ical region for PWS. A submicroscopic deletion that con-
ferred AS when maternally inherited, but did not confer
PWS when paternally inherited, defines the downstream
border of the proposed minimal critical region (Hamabe
et al. 1991). We have mapped the genomic locations of
these borders in the Human Genome Working Draft,
December 2001 version. The breakpoint cluster region is
downstream of EST AI205506, which maps to nucleo-
tides (nts) 22057217–22057639 (Wirth et al. 2001). The
upstream breakpoint of the AS submicroscopic deletion
was identified at nt 22178529, ∼4 kb downstream of
PAR-1 and 28 kb upstream of the HBII-52 snoRNA
cluster (Greger et al. 1993). The almost 121-kb region
between these boundaries likely contains a gene (or
genes) whose loss of expression confers, or contributes
significantly to, the phenotype of PWS (fig. 1B).
Reports 671
The distal breakpoint cluster region can define an up-
stream border of a minimal critical region for PWS only
if most of the individuals with this translocation break-
point fulfill the diagnostic criteria for PWS (Holm et al.
1993). If they do not, it is important to identify features
that consistently distinguish these individuals from those
with PWS and proximal translocation breakpoints, so
that potential contributions of genes in the intervening
region to the full PWS phenotype may be determined
(fig. 1B; SNRPN and snoRNAs HBII-436/13/437). The
possibility that a clinical distinction exists between in-
dividuals with SNRPN promoter-proximal and promoter-
distal balanced reciprocal translocation breakpoints is
suggested by the original reports of these patients, but
it must be critically assessed. The two individuals with
proximal translocation breakpoints were described as
having typical PWS (Sun et al. 1996; Kuslich et al. 1999),
whereas two of the three individuals with distal trans-
location breakpoints were described as having atypical
PWS phenotypes (Schulze et al. 1996; Conroy et al.
1997; Wirth et al. 2001).
Individual features of PWS are variably present in per-
sons with the standard deletion or maternal UPD 15.
Therefore, prior to the development of sensitive and spe-
cific molecular tests for PWS, a point system of 8 major
criteria (neonatal hypotonia with poor suck, failure to
thrive requiring special feeding techniques, hyperphagia,
obesity after 1 year of age, hypogonadotropic hypogon-
adism, global developmental delay, characteristic facies,
and chromosomal abnormality affecting the 15q11-13
region) and 11 minor criteria was established, to aid in
diagnosis (Holm et al. 1993). Each major criterion ful-
filled earns 1 point, and each minor criterion earns 1/2
point. A score of 8 points, with at least 4 from the major
criteria, supports a diagnosis of PWS. Each of the five
individuals with translocations within SNRPN was re-
ported separately, by different authors, and was evalu-
ated by different clinicians. In the original reports, the
two individuals with proximal translocation breakpoints
were reported to meet PWS clinical diagnostic criteria,
and each had a score 18 points. The individual described
by Kuslich et al. (1999) was reported to have a score of
10 but actually had a score of 11 (1 point added for
characteristic facies). The individual reported by Sun et
al. (1996) had a score of 10. Both of these individuals
met all of the major clinical diagnostic criteria for PWS.
Two of the three individuals with distal translocations
also met criteria for PWS, with scores of 9 points
(Conroy et al. 1997) and 9.5 points (Schulze et al.
1996) (reported as 8.5 points but with 1 point added
for neonatal hypotonia). One of these individuals was
reported to have atypical PWS, because he did not have
hypogonadism or failure to thrive, although he did re-
quire special feeding techniques in the neonatal period
(Conroy et al. 1997). The individual described by Wirth
et al. (2001) was also reported to be atypical and had
a clinical score of 7.0 points (reported as 6.5 points but
with 1/2 point added for articulation defects). She did
not meet the major criteria of neonatal hypotonia with
poor suck, feeding problems with failure to thrive, or
characteristic facies.
Our review of the reports of these patients and our
reassessment of clinical scores indicate that it is difficult
to reproducibly employ the diagnostic criteria. In ad-
dition, application of the diagnostic clinical criteria to
individuals who have the standard deletion or maternal
UPD 15 does not identify all of them as having PWS. A
recent review of the clinical features of 90 individuals
who had PWS, confirmed by standard molecular diag-
nostic tests and evaluated by the same clinician, found
that 17% did not meet clinical diagnostic criteria for
PWS (Gunay-Aygun et al. 2001). Given the small num-
ber of individuals reported to have balanced reciprocal
translocations within the SNRPN locus—and given the
fact that no feature of PWS was consistently different
between the two groups—we find that we cannot dis-
tinguish between those with promoter-proximal and
promoter-distal translocations. Because two of three in-
dividuals with SNRPN promoter-distal translocations
meet clinical diagnostic criteria for PWS and because
these criteria do not identify all individuals with the
standard deletion as having PWS, we have chosen the
promoter-distal translocation breakpoint cluster region
as the upstream boundary of a proposed minimal critical
region for PWS.
The assignment of the distal breakpoint cluster region
as the upstream boundary of the proposed minimal crit-
ical region suggests that lack of expression of thePWCR1/
HBII-85 snoRNA cluster and/or of HBII-438A may be
responsible for many or all of the features of PWS. These
snoRNAs appear to be the only putative functional mol-
ecules encoded within this region (fig. 1B). The PWCR1/
HBII-85 snoRNAs are highly conserved between the hu-
man and mouse genomes (Cavaille et al. 2000; de los
Santos et al. 2000; Meguro et al. 2001). Other stable
transcripts from this region (PWCR1, IPW, and PAR-1)
have limited coding potential and are minimally (PWCR1
and IPW) or not at all (PAR-1) conserved between human
and mouse genomes (Sutcliffe et al. 1994; Wevrick et al.
1994; Wevrick and Francke 1997; de los Santos et al.
2000). Recent evidence suggests that these transcripts are
portions of large transcripts that originate at the SNRPN
promoter and may extend to UBE3A. It appears likely
thatPWCR1, IPW, andPAR-1 and other transcripts distal
to the SmN coding region that lack coding potential are
stable processing intermediates of these hypothetical large
SNRPN transcripts (Runte et al. 2001). The only portions
of the PWCR1 transcript that are conserved in the mouse
ortholog Pwcr1 correspond to snoRNA sequences; this
conservation first identified snoRNAs within the PWS re-
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gion (de los Santos et al. 2000). The PWCR1 transcript
may be stabilized by the presence of snoRNA sequences
at the 5′ and 3′ ends that allow RNA duplex stem for-
mation and/or bind snoRNP proteins (Kiss 2002). The
putative SNRPN exon within PWCR1 is likely skipped
because it has mutated splice sites, and, as a consequence,
the two snoRNAs within it are likely not appropriately
processed.
The hypothesis that loss of PWCR1/HBII-85 snoRNA
expression is crucial for PWS is supported by mouse
models of PWS, although the genomic characterization
of the conserved syntenic region on mouse chromosome
7C is incomplete, and the upstream breakpoint of a cru-
cial deletion mouse (Johnson et al. 1995; Tsai et al. 1999;
Nicholls and Knepper 2001) has not been published.
Therefore, a similarly detailed analysis is not possible.
In addition, the mouse orthologs of HBII-438A, HBII-
436, and HBII-437 have not been described to date.
There are several mouse models of PWS, although the
affected mice exhibit only one or two aspects of the
human PWS phenotype. All mice with maternal UPD
for the portion of chromosome 7 that is in conserved
synteny with human chromosome 15q11-13 exhibited
failure to thrive and died within 8 d of birth (Cattanach
et al. 1992). This is believed to be similar to the failure-
to-thrive phenotype of human newborns with PWS.
In an attempt to identify the genes responsible for the
mouse phenotype, mice have been engineered to have
partial deletions of the region. Mice with paternal in-
heritance of a deletion in the IC also all died within 1
wk of birth (Yang et al. 1998). Mice with inherited pa-
ternal deletions of portions of Snrpn (or Snurf) that dis-
rupt protein function had no detectable abnormal phe-
notype (Yang et al. 1998; Tsai et al. 1999); however,
mice with a deletion from exon 2 of Snrpn to exon 2
of Ube3a exhibited 80% postnatal lethality, as well as
growth retardation and hypotonia (Tsai et al. 1999). In
contrast to findings in humans with PWS, mice that
survived the neonatal period did not develop hyperpha-
gia and obesity, and they were fertile (Tsai et al. 1999).
Other aspects of the human phenotype are difficult to
assess in mice. The results reported by Tsai et al. (1999)
indicate that loss of expression of a gene or genes be-
tween exon 2 of Snrpn and Ube3a is responsible for the
mouse phenotype. If the Snrpn locus is also the host
gene for the orthologous snoRNAs in mice and if there
are no other genes in this interval, these data would
support a role for loss of expression of Snrpn-encoded
snoRNAs for the mouse phenotype.
The hypothesis that absence of expression of the
PWCR1/HBII-85 snoRNAs is crucial for the patho-
genesis of PWS predicts that the expression of these sno-
RNAs should be absent in the individuals with PWS who
have balanced reciprocal translocations. These snoRNAs
are not expressed in brain of individuals with nontrans-
location PWS (Cavaille et al. 2000; de los Santos et al.
2000). The PWCR1/HBII-85 snoRNAs were discovered
after the reports of four of the five balanced transloca-
tion patients and were assayed directly only in one, in
whom they were not expressed (Wirth et al. 2001). It is
particularly important to determine PWCR1/HBII-85
snoRNA expression in the two patients with proximal
translocation breakpoints, because cells from these pa-
tients have been reported to express IPW and PAR-1,
which are encoded within the minimal critical region,
IPW, and PAR-1 (Sun et al. 1996; Kuslich et al. 1999)
(fig. 1). If these individuals with PWS express the
PWCR1/HBII-85 snoRNAs appropriately, then loss of
expression of these is unlikely to contribute significantly
to the phenotype of PWS.
Here, we report our studies of SNRPN transcripts in
fibroblasts of the individual with t(4;15)(q27;q11.2). In
the original study of this individual, Kuslich et al. (1999)
used RT-PCR to show that interspecies somatic cell hy-
brids containing the der(4) chromosome did not express
SNRPN exons 3–5, which are located downstream of
the breakpoint, or the more distal PAR-5. The latter had
been identified as a stable paternally imprinted transcript
but is now known to be a portion of SNRPN intron 12
(fig. 1A). In contrast, they reported expression of the
downstream transcripts IPW and PAR-1. These tran-
scripts were also initially identified as independent im-
printed transcripts, but IPW comprises sequences from
intron 58 and exons 59–61 of SNRPN, and PAR-1 con-
sists of sequences of exon 61 and intron 62 (Human
Genome Browser). As mentioned above, these are likely
to be stable processing intermediates of the hypothetical
large SNRPN transcripts, and they are encoded within
the proposed PWS minimal critical region (fig. 1B). Their
expression in cells derived from this patient would imply
the presence of an alternative or cryptic promoter down-
stream of PAR-5/intron 12 and upstream of IPW/intron
58. This would suggest that snoRNAs downstream of
PAR-5, including the PWCR1/HBII-85 and HBII-438A
snoRNAs within the proposed minimal critical region,
might also be transcribed and produced (fig. 1A and
1B). To clarify the role of the snoRNAs in PWS, we
determined expression of several of them in skin fi-
broblasts of the individual with t(4;15) by quantita-
tive RT-PCR. We also assayed the expression of ad-
ditional introns and exons of the SNRPN transcript,
including IPW and PAR-1.
A karyotype confirmed the previously described
t(4;15)(q27;q11.2) balanced translocation in the fibro-
blasts (data not shown). FISH demonstrated that both
the der(15) and der(4) chromosomes contain sequences
that hybridize to an SNRPN probe (Vysis), indicating
that the translocation breakpoint on chromosome 15
is within SNRPN (fig. 2). The precise location of the
breakpoint within SNRPN was confirmed by RT-PCR;
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Figure 2 Results of FISH of fibroblast chromosomes with a
t(4;15)(q27;q11.2) balanced reciprocal translocation. The chromo-
some 15 centromeric (cen) probe (green) identifies the normal chro-
mosome 15 (left) and the der(15) (middle). The SNRPN probe (pink)
hybridizes to the normal chromosome 15 (left), the der(15) (middle),
and the der(4) (right), demonstrating that the breakpoint is within
SNRPN. The distal chromosome 15q22 probe (yellow) identifies the
normal chromosome 15 (left) and the der(4) (right).
SNRPN exon 2 is expressed, and SNRPN exon 3 is not,
as reported elsewhere (Kuslich et al. 1999) (table 1).
Our expression analysis of IPW and PAR-1 revealed
that neither of these is expressed in fibroblasts of this
individual. Conventional RT-PCR of IPW expression
produced equivocal results. The primers used are located
in the portion of IPW that corresponds to SNRPN intron
58, and they amplify genomic DNA. RNA was treated
with DNase I prior to reverse transcription. The RT
control reaction amplified product, although the band
was not as intense as that for the RT reaction (data
not shown). Therefore, we evaluated IPW expression by
quantitative RT-PCR, using SYBR Green as a detection
reagent (Applied Biosystems). SYBR Green fluoresces
when bound to double-stranded DNA. Product ampli-
fication is detected by the change in fluorescence at each
cycle of PCR. The PCR cycle at which product is sig-
nificantly amplified above background is related to the
amount of starting material and is called the threshold
cycle (CT) (fig. 3) (Ginzinger 2002). Results reported
here are relative, not absolute, and are interpreted by
comparison to a standard curve produced by serial di-
lutions of pooled cDNA. To control for cell number,
results are normalized to those of a housekeeping gene.
This method allows relative quantification between sam-
ples of the amount of cDNA representing a transcript
of interest. To facilitate reliable quantification, primers
are designed to amplify small products, ∼50 nts. To en-
sure accurate quantification, reactions are performed in
triplicate. To ensure that the correct product has been
amplified, product size is confirmed by agarose gel elec-
trophoresis. The IPW primers used were specified by the
Applied Biosystems Primer Express program and do not
span an intron. They are located within SNRPN exon
61. cDNA from fibroblasts of an unaffected control
subject matched for age and sex (10-year-old boy) was
prepared and assayed in parallel. The amplification plots
demonstrate that fibroblasts of the individual with t(4;15)
do not express IPW above the background identified in
the RT control (fig. 3A; compare the t(4;15) amplifi-
cation plot to those of the two RT controls). Similar
results were obtained for PAR-1 and for SNRPN exons
57–58 (data not shown and table 1).
In repeat experiments, we analyzed expression of these
SNRPN derived transcripts using, as additional controls,
lymphoblasts from an individual with AS and a maternal
15q11-q13 deletion confirmed by FISH and fibroblasts
from an individual with PWS confirmed by methylation
testing SNRPN exon 1 in parallel with the t(4;15) cDNA
and the original unaffected control subjects (AS: 7-year-
old boy; PWS: 38-year-old woman). This confirmed that
the t(4;15) fibroblast results were similar to those of the
PWS fibroblasts; the AS lymphoblast results were similar
to those of the normal control fibroblasts (table 1). Al-
though the t(4;15) sample appears to have some ex-
pression over the background of the RT control (ta-
ble 1), this does not appear to be significant, because,
at high CT values, which are essentially negative re-
actions, there is considerable variability between rep-
licas, (fig. 3C) for the t(4;15) RT samples and the
RT samples. Therefore, RT reactions were repeated
in triplicate, to confirm the overlap between RT and
RT amplification plots for the t(4;15) cells (SNPRN
exons 3, 57, and 58; data not shown).
Our quantitative RT-PCR results clearly demonstrate
that IPW and PAR-1 are not expressed in fibroblasts of
the individual with t(4;15) and PWS. Although Kuslich
et al. (1999) used lymphoblast-derived interspecies so-
matic hybrid cells, we do not believe that the difference
in cell type accounts for the apparent difference in re-
sults. The IPW primers used by Kuslich et al. also do
not span an intron and are located within exon 61. Rec-
ommendations for RT-PCR are that PCR primers span
introns so that contaminating genomic DNA is not de-
tectably amplified. This is not always possible, as in the
case of the intronless transcript PAR-1. Because of the
possibility that genomic DNA may be amplified, a RT
control should always be included in the analysis. In the
absence of this control, RT-PCR data are not conclusive,
particularly when the PCR primers used do not span
introns. Kuslich et al. did not perform a RT reaction
in parallel but used different primer sets that spanned
introns to demonstrate a lack of genomic DNA ampli-
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Table 1
Quantitative RT-PCR Data from Normal Control Fibroblasts, AS Lymphoblasts, PWS
Fibroblasts, and t(4;15) Fibroblasts
Transcripta
Normal
Fibroblasts
AS
Lymphoblasts
PWS
Fibroblasts
t(4;15)
Fibroblasts
SNRPN exon 2 .8 (.009) .9 (.0004) .0006 (.001) 2.1 (.007)
SNRPN exon 3 2.8 (.03) 2.7 (.001) .002 (.002) .02 (.008)
SNRPN exon 57/58 1.6 (.001) 1.9 (.001) .001 (.001) .01 (.001)
IPW 2.5 (.16) 2.5 (.001) .01 (.02) .05 (.12)
PAR-1 3.1 (.11) 2.4 (.13) .5 (.3) .3 (.005)
U21 1.5 (NC) 1.4 (NC) .6 (NC) 1.4 (NC)
PWCR1/HBII-85 3.3 (.01) 1.7 (.04) .01 (.02) .01 (.02)
NOTE.—Data are relative number of nanograms of the transcript of interest (RT
results). CT PCR values from amplification plots, as in figure 3, were interpreted on the
basis of a standard curve and were normalized to data for b-actin for each cell type. NC
indicates that all RT reactions gave no signal and so no value was calculated (CT 140).
Primer sequences are as follows: SNRPN exon 2: 5′-ACGAACTACAGAACAGCACGT-
ACC-3′ and 5′-CTGCGTTTGACTTGGACTTCC-3′; SNRPN exon 3, 5′-TTCTCAGCAG-
CAGCAAGTACCT-3′ and 5′-TGCCTCAGTTCAGCCTGGA-3′; SNRPN exon 57/58,
5′-CAGGAAAGATCAAAACGATGCA-3′ and 5′-GGCAGCTATCTGGACCAATCAC-3′;
IPW, 5′-TGCATTCTTTTAGTGGATAGATGCA-3′ and 5′-TCCCCATAATGGCTTGTG-
TGT-3′; PAR-1, 5′-AGAGGCCAGCCATAACTAGCC-3′ and 5′-TGAAGAGCGTTCCCC-
TGTG-3′;U21, 5′-TGAGCAGTCAGTAGTTGGTCCTTT-3′ and5′-GAAACAATTATCG-
CATCATATGCAA-3′; PWCR1/HBII-85, 5′-TCGATGATGAGTCCCCCATAA-3′ and 5′-
CATTTTGTTCAGCTTTTCCAAGG-3′.
a IPW and PAR-1 are stable transcripts from the SNRPN locus. U21 is a ubiquitously
expressed nonimprinted C/D box snoRNA encoded on chromosome 1. PWCR1/HBII-85
primers recognize 4 of 27 PWCR1/HBII-85 snoRNA sequences.
fication in theirRT samples; however, different primer
pairs may give different amounts of background ampli-
fication from the same DNase I–treated samples (fig. 3;
compare RT controls in panels A–C). Therefore, be-
cause of the absence of aRT control in their expression
analysis, the data of Kuslich et al. do not demonstrate
conclusively that IPW and PAR-1 are expressed in the
cell type of the individual with t(4;15) PWS that they
assayed. Of the seven transcripts downstream of the
translocation breakpoint assayed in their work, only
IPW and PAR-1 were apparently expressed. Because
these data are not conclusive, we suspect that no SNRPN
locus sequences downstream of the translocation break-
point are expressed in the cells assayed by Kuslich et al.
It was not possible to obtain these cells to test this.
Our results indicate that SNRPN locus sequences
downstream of the translocation breakpoint are not ex-
pressed in fibroblasts of the individual with t(4;15) PWS.
This finding predicts that the snoRNAs encoded within
SNRPN are not expressed either, because these are all
derived from SNRPN introns downstream of the trans-
location breakpoint. Because we have shown that IPW
and PAR-1 are not expressed in the t(4;15) fibroblasts
there is no evidence for a cryptic promoter or other ac-
tivation of expression of sequences downstream of PAR-
5, and there is no reason to expect that the snoRNAs
are transcribed and produced. To confirm this, we used
quantitative RT-PCR to determine expression of several
of the SNRPN encoded snoRNAs. The ubiquitously ex-
pressed, nonimprinted, U21 snoRNA encoded on chro-
mosome 1 served as a control. Amplification plots for
U21 demonstrate that U21-containing sequences are de-
tected, in approximately equivalent amounts, in both the
t(4;15) fibroblasts and the control fibroblasts (normal-
ized to b-actin; data not shown) (fig. 3B). The analysis
was repeated with the additional controls described
above (table 1). Sequence comparison reveals that the
27 PWCR1/HBII-85 snoRNAs can be divided into three
classes (Runte et al. 2001). Class I is very similar to the
more homogeneous mouse MBII-85 snoRNAs (Cavaille
et al. 2000; B.P., unpublished results). One primer pair
was designed that should amplify four of nine PWCR1/
HBII-85 snoRNAs in class I. This primer pair gave no
amplification above background from t(4;15) fibroblast
cDNA or from cDNA of the PWS control fibroblasts
(fig. 3C and table 1). Amplification above background
was detected from cDNA of normal control fibroblasts
and from cDNA of AS lymphoblasts (fig. 3C and table
1). Thus, the PWCR1/HBII-85 snoRNAs are detected
in fibroblasts of a normal control individual and in lym-
phoblasts of an individual with AS, but they are not
detected in control PWS fibroblasts or in fibroblasts of
the individual with t(4;15) PWS.
There are multiple additional snoRNAs encoded
within the SNRPN transcript (fig. 1A). We evaluated the
expression of snoRNAs HBII-436 and HBII-437. We
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Figure 3 Amplification plots of quantitative RT-PCR of cDNA
from fibroblasts of the individual with t(4;15) and fibroblasts of a
normal control for three transcripts: A, IPW; B, U21 snoRNA; C,
PWCR1/HBII-85 snoRNAs. The Y-axis is the amount of fluorescence.
The X-axis is the PCR cycle number. Each RT reaction was done in
triplicate, but not all individual plots can be distinguished, because
they are superimposed. IPW and PWCR1/HBII-85: t(4;15) RTs are
shown in red, yellow, and green; RTs are shown in red and dark
blue. The RT reactions, performed in parallel, gave similar results
for both cell types and have not been labeled individually. In all cases,
a no-DNA control was included. The CT values of these reactions were
generally 140, but, with IPW primers, the value was 39. Samples with
more starting cDNA of a transcript cross CT at a lower PCR cycle
(e.g., the t(4;15) fibroblasts have more U21 cDNA than do the control
fibroblasts).
detected amplification product above background in
control but not in t(4;15) fibroblasts with primers for
both of these (data not shown). The sequence of HBII-
437 has degenerate D and D′ box sequence elements and
was not detected by northern blot analysis (Runte et al.
2001; it may not be a stable snoRNA. We also attempted
to assay HBII-52 snoRNA expression. There are 47
HBII-52 snoRNAs in two classes (Cavaille et al. 2000;
Runte et al. 2001). Only three (HBII-52 snoRNAs 17–
19) are identical in sequence, and these constitute class
II (Runte et al. 2001). We designed a primer pair to
detect the HBII-52 snoRNA 17/18/19 sequence. These
primers amplified product from cDNA of a normal con-
trol brain but not from that of a brain of an individual
with PWS (data not shown). No product was amplified
from either the control fibroblasts or the AS lymphoblasts
or from the t(4;15) or PWS fibroblasts (data not shown).
These results are consistent with the demonstration, de-
scribed elsewhere by Cavaille et al. (2000), that theHBII-
52 snoRNAs are detected only in the brain.
Although our analysis of gene expression was per-
formed in fibroblasts and, thus, may not reflect tissue-
specific and cell type–specific expression within the brain
(the critical affected organ in PWS), peripheral tissues
are the only ones to which we have access for these rare,
living patients with translocations. All gene expression
studies of these individuals have, of necessity, been per-
formed in fibroblasts or lymphoblasts, and all conclu-
sions derived from these studies are limited by this fact.
Our data indicate that the previously published expres-
sion analysis, which suggested that some of the SNRPN-
encoded snoRNAs might be expressed in the individual
with PWS and t(4;15) was misinterpreted and that
SNRPN locus sequences downstream of the breakpoint
are not expressed in peripheral cells of this individual.
Although we cannot assay SNRPN expression in the
brain of this individual, we suggest that our results
remove one challenge to the hypothesis that loss of
PWCR1/HBII-85 snoRNA expression contributes sig-
nificantly to the phenotype of PWS (Kuslich et al. 1999;
Nicholls and Knepper 2001; Wirth et al. 2001). There
is yet another challenge to this hypothesis. In fibroblasts
of the individual with PWS and a t(19;15) (the chro-
mosome 15 breakpoint is also within SNRPN intron 2),
SNRPN exons immediately downstream of the break-
point, as well as PAR-5, IPW, and PAR-1 were reported
to be expressed (Sun et al. 1996) (fig. 1). The IPW pri-
mers used in this work do span an intron, and the RT
control had no detectable product. (The PAR-1 and PAR-
5 primers did not span introns; the PAR-1 RT control
had diffuse product amplification; and the PAR-5 RT
control had no amplification.) Two primer pairs were de-
signed to detect SNRPN exons 1–2 (first pair) and exons
3–9 (second pair). Exons 1 –2 were expressed, as was
expected, but exons 3–9, downstream of the breakpoint,
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were also expressed. Expression of snoRNAs was not
evaluated, because these had not yet been identified, but
it is likely that the intron-encoded snoRNAs are also
detectably produced in these fibroblasts, because the ex-
ons appear to be transcribed. We suggest that translo-
cation to a gene-rich and/or transcriptionally active re-
gion of chromosome 19 has resulted in a transcript that
extends into SNRPN exons on der(19) in the fibroblasts
studied, as was suggested originally by Sun et al. (1996).
Processing of this transcript could lead to the generation
of the SNRPN intron-encoded snoRNAs. Because this
individual has PWS but may express the SNRPN-en-
coded snoRNAs at some level in some tissues, we suggest
that expression of the fusion transcript is either too low
to confer normal function, is not present in the appro-
priate cell type(s), and/or lacks the correct developmental
regulation. To distinguish between these possibilities, it
will be necessary to identify the gene on chromosome
19 to which the SNRPN transcript has been fused, to
determine the level of expression quantitatively, and/or
to determine the expression of the putative chromosome
19 gene/SNRPN fusion transcript in additional tissues.
The function of the RNAs whose loss may be crucial
for the development of PWS is unknown. C/D box
snoRNAs are characterized by short sequence ele-
ments (the C, C′, D, and D′ boxes) (Kiss 2002). These
elements bind proteins that stabilize these nontrans-
lated RNAs and are important for their nucleolar lo-
calization (Samarsky et al. 1998; Kiss 2002). The nu-
cleolus is the site of ribosome biogenesis; most C/D box
snoRNAs direct 2′-O-ribose methylation of ribosomal
RNA (rRNA) (Kiss 2002). The role of this methylation
is not known. The sequence upstream of the D or D′
box of these snoRNAs is complementary to the region
of rRNA in which the modified nt resides. There are
1100 such modifications in vertebrate rRNA, and cor-
responding snoRNAs have been identified for many of
these sites (Huttenhofer et al. 2001). Some C/D box
snoRNAs methylate snRNAs involved in splicing, others
modify tRNA. Finally, a growing number lack comple-
mentarity to rRNA, snRNA, or tRNA (Huttenhofer et
al. 2001; Jady and Kiss 2000; Kiss 2002). These are
termed “orphan snoRNAs,” because their targets, which
are presumed to be RNAs, have not yet been identified.
The snoRNAs encoded within the SNRPN introns fall
into this category (Cavaille et al. 2000; de los Santos et
al. 2000; Meguro et al. 2001). Their targets, the mod-
ification(s) they direct, and the molecular and cellular
function(s) they affect are unknown. It has been sug-
gested that some orphan snoRNAs may target mRNA.
The HBII-52 snoRNAs have a striking 18-nt comple-
mentarity to mRNA of serotonin receptor 2c, in a region
that is both edited and alternatively spliced (Cavaille et
al. 2000); however, no alteration of serotonin receptor
structure or function in cells lacking HBII-52 has yet
been reported. In addition, these snoRNAs appear not
to be crucial for the pathogenesis of PWS, because they
are absent in an apparently normal woman who inher-
ited the submicroscopic deletion from her father (Ham-
abe et al. 1991; Greger et al. 1993).
Analysis of the available data has led us to propose
that the minimal critical region for PWS is ∼121 kb and
that it contains the PWCR1/HBII-85 snoRNA cluster
and the HBII-438A snoRNA as the only putative func-
tional genes. We recognize that this proposal is limited
by the fact that it is based on analysis of individuals
who have PWS and a translocation breakpoint within
SNRPN, rather than deletions of the minimal critical
region. Gene expression has been assayed only in pe-
ripheral tissues of these individuals, not in cells of the
critical organ affected in PWS, the brain. We cannot
confirm that SNRPN sequences upstream of the trans-
location breakpoint are expressed and that SNRPN
sequences downstream of the translocation break-
points are not expressed in the crucial cell types within
the brain. Testing of our hypothesis will require further
work in both mice and humans regarding the role of the
products of the SNRPN/Snrpn locus in brain function.
That the snoRNAs encoded within the proposed crit-
ical region are functional has not yet been demon-
strated; however, they have canonical C and D boxes
(Kiss 2002). PWCR1/HBII-85 snoRNAs are highly con-
served between human and mouse and have been iden-
tified as stable molecules, by northern blot analysis (Ca-
vaille et al. 2000; de los Santos et al. 2000; Runte et al.
2001).
The demonstration that IPW, PAR-1, and, most im-
portant, four of the PWCR1/HBII-85 snoRNAs encoded
by SNRPN are not expressed in fibroblasts of the in-
dividual with t(4;15) and PWS removes an important
barrier to the conclusion that loss of expression of the
snoRNAs in the proposed minimal critical region con-
tributes to, or is responsible for, the phenotype of PWS.
To further evaluate this hypothesis, expression of the
PWCR1/HBII-85 snoRNAs should be assayed in those
rare patients whose phenotype suggests PWS but whose
molecular test results are unusual (Dupont et al. 1999;
Gillessen-Kaesbach et al. 1999). Loss of expression of
additional genes encoded by the large SNRPN tran-
scripts may also contribute to the phenotype of PWS. A
true understanding of the pathogenesis of PWS will be
possible only when the targets of the many snoRNAs
have been identified, the nature of the modification(s)
the snoRNAs direct clarified, and the cellular function(s)
of these modifications brought to light.
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